CTOs on the Move

Fallbrook Engineering

www.fallbrook-eng.com

 
Fallbrook Engineering is a Valley Center, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Partners Pharmacy

Partners Pharmacy is a long-term care pharmacy company in the United States. We offer a full range of services and resources to effectively serve the comprehensive medication needs of residents of skilled nursing facilities, assisted living communities, and alternative care facilities. Our unique AP PassPort™ has dramatically improved medication availability for residents, reduced medication management time for nursing, and improved compliance. Partners Pharmacy currently services over 40,000 beds with services areas in Connecticut, Florida, Maryland, Massachusetts, New Jersey, New York, Pennsylvania, Texas, and Virginia. Each location offers unparalleled, personalized service through the combined resources of our local teams and our expanding regional resources. Together we partner with the facilities we service to improve outcomes and reduce costs.

Children's Psychological Health Center

Children's Psychological Health Center is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cornell Scott-Hill Health Center

Cornell Scott-Hill Health Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Cornell Scott-Hill Health Center is based in New Haven, CT. You can find more information on Cornell Scott-Hill Health Center at www.hillhealthcenter.com

Burbank HealthCare Foundation

Burbank HealthCare Foundation is a Burbank, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Portola

Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.